目的：观察氟替卡松吸入治疗儿童哮喘的效果。
AIM: To observe the effects of the inhaled fluticasone in treating pediatrics asthma.
目的制备具有良好喷雾特性的丙酸氟替卡松鼻喷雾剂。
AIM To prepare the fluticasone propionate nasal spray of good spray characteristics.
主要比较每周两次使用氟替卡松和安慰剂进行维持治疗对预防病情恶化的疗效。
The primary outcome was the efficacy of twice weekly maintenance treatment with fluticasone propionate ointment in preventing exacerbations of atopic dermatitis compared with placebo ointment.
两项研究证明氟替卡松安特酰胺鼻腔喷雾治疗并不影响这些重要的生长指标和激素功能。
Both studies demonstrated that treatment with FFNS did not affect these important indicators of growth and hormonal function.
在早期先行性实验中，研究者用口服较稠的布地奈德成功地治疗了两位不能使用丙酸氟替卡松的病人。
In an earlier, pilot study, researchers used oral viscous budesonide to successfully treat two patients who had been unable to utilize fluticasone propionate.
在两项与安慰剂相对照的研究中均发现氟替卡松安特酰胺鼻腔喷雾能有效减轻鼻部症状且通常耐受良好。
In both studies FFNS was found to be effective in reducing nasal symptoms, compared to placebo, and was generally well-tolerated.
强的松降低血中嗜酸细胞计数，而氟替卡松降低气道嗜酸细胞计数，这提示氟替卡松的抗炎作用表现在局部。
Prednisone reduced blood eosinophil counts, while fluticasone reduced airway eosinophil counts, suggesting that the anti-inflammatory performance of fluticasone is exerted locally.
以双氟美松为原料，经氧化、酯化、酰化、醇解和氟甲基化反应制得氟替卡松丙酸酯（1），总收率60。
Fluticason propionate(1) in overall yield of 60.1% was synthesized from Flumethasone by oxidation, esterification, acylation, alcoholysis and fluoromethylation.
这些鼓舞人心的资料表明：氟替卡松安特酰胺鼻腔喷雾是临床医生和父母治疗变态反应性鼻炎患儿症状的一种新的选择。
These encouraging data suggest that FFNS could offer clinicians and parents a viable new treatment option for children with nasal allergies.
盐酸氮卓斯汀组和丙酸氟替卡松组的总有效率分别为83.78%和90.00%，两组差异无统计学意义（P>0.05）。
There was no significant difference between the total response rate of azelastine hydrochloride and of fluticasone propionate(83.78% vs 90.00%, P>0.05).
对558名2 ~11岁常年性变态反应性鼻炎患儿进行另一项研究，以安慰剂组为对照，比较氟替卡松安特酰胺鼻腔喷雾110mcg和55mcg长期治疗的效果。
Another study compared the effects of long-term treatment with FFNS at 110 MCG and 55 MCG, versus placebo, of year-round allergies in 558 children ages 2 through 11.
对558名2 ~11岁常年性变态反应性鼻炎患儿进行另一项研究，以安慰剂组为对照，比较氟替卡松安特酰胺鼻腔喷雾110mcg和55mcg长期治疗的效果。
Another study compared the effects of long-term treatment with FFNS at 110 MCG and 55 MCG, versus placebo, of year-round allergies in 558 children ages 2 through 11.
应用推荐